VectorY Secures New Financing for Vectorized Antibodies

Company VectorY Therapeutics Event Type Financing (€74.5 million; EIB convertible loan and Invest-NL) Modality AAV-delivered vectorized antibody Asset VTx-002 Target TDP-43 pathology Disease Area Amyotrophic lateral sclerosis Summary VectorY announced November 11 €74.5 million in new financing for its clinical and preclinical neurodegeneration pipeline. Investor…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *